Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

• Main Authors: Wenyuan Xiong (Author), Manja Friese‐Hamim (Author), Andreas Johne (Author), Christopher Stroh (Author), Manfred Klevesath (Author), Gerald S. Falchook (Author), David S. Hong (Author), Pascal Girard (Author), Samer El Bawab (Author)
• Format: Book
• Published: Wiley, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Tepotinib is a highly selective and potent MET inhibitor in development for the treatment of patients with solid tumors. Given the favorable tolerability and safety profiles up to the maximum tested dose in the first‐in‐human (FIH) trial, an efficacy‐driven translational modeling approach w...